N-Xone TZ Injection is a combination antibiotic formulation containing Ceftriaxone 1000 mg and Tazobactam 125 mg, designed for the treatment of a broad spectrum of bacterial infections. Ceftriaxone, a third-generation cephalosporin, exhibits potent bactericidal activity by inhibiting bacterial cell wall synthesis, while Tazobactam, a beta-lactamase inhibitor, enhances the efficacy of Ceftriaxone by preventing the degradation of the antibiotic by beta-lactamase-producing bacteria. This synergistic combination is effective against a wide range of gram-positive and gram-negative pathogens, including resistant strains. N-Xone TZ Injection is indicated for serious infections such as lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and bone and joint infections. It is administered via intramuscular or intravenous routes, ensuring rapid systemic absorption and therapeutic plasma concentrations. Dosage and duration of therapy should be guided by the severity of infection, renal function, and clinical response. Caution is advised in patients with hypersensitivity to beta-lactam antibiotics. Common adverse effects may include local injection site reactions, gastrointestinal disturbances, and hypersensitivity reactions. N-Xone TZ Injection should be used under strict medical supervision with appropriate microbiological monitoring to optimize clinical outcomes and minimize resistance development.